Autopsy report · NCT03009110

Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial

“DSMB recommendation following interim analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 9 months before it stopped.
• 1,624 participants enrolled.
• Results were posted on the registry 3 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Indiana University

Sponsor type

University, hospital or other

Conditions

Surgical Wound Infection; Cesarean Section

Interventions

Prophylactic NPWT; Standard Dressing

Participants

1,624

Sites

6

Countries

United States

Trials that died the same way

• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
  “DSMB recommendation based on programmed interim analysis.” (92% match in meaning)
• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (80% match in meaning)
• Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
  “DSMB recommendation (futility)” (78% match in meaning)
• Thiamine as a Metabolic Resuscitator After Cardiac Arrest
  “DSMB recommendation based on differing mortality in a subgroup analysis” (71% match in meaning)
• Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
  “The study treminated early according to DSMB recommendantions” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.